ANABOLICRX

The education library

Primobolan Depot and metenolone: medical evidence and its limits

← All education profiles

Educational evidence summary, not personal medical advice. AI-assisted research and editorial preparation by AnabolicRX. Sources checked 23 October 2026. No independent clinical review completed. Current Canadian product authorization is not established by this article.

Identity: similar names can conceal different evidence

Metenolone is also spelled methenolone in the research literature. Primobolan Depot refers to an injectable enanthate formulation; oral methenolone research is not automatically evidence for that formulation. Neither name should be confused with methandrostenolone, a different drug discussed in the Dianabol profile. That distinction matters because broad searches can return studies about the wrong substance.

The Spanish medicines regulator's product information identifies the depot product as metenolone enanthate. It describes slow release followed by separation of the ester into metenolone and enanthic acid. Its indications concern catabolic illness and wasting, including selected advanced cancers; it expressly excludes muscle or performance enhancement in healthy people. This is Spanish product information, not proof of Canadian authorization. AEMPS product information

Medical history: follow the disease and the endpoint

Metenolone's historical research includes advanced breast cancer and disorders of blood-cell production. The questions were whether people with serious illness experienced remissions, improved blood counts or longer survival. They were not studies establishing a general wellness benefit in healthy adults.

A 1968 clinical-trial citation documents investigation of methenolone enanthate in advanced breast cancer. The accessible record has no abstract, so this review does not claim its results. Establishing that a study exists is different from establishing that its treatment succeeded. Kennedy and Yarbro, 1968

The evidence summarized below comes primarily from accessible abstracts. It is not a full systematic review, a current treatment guideline or an independently reviewed clinical reference.

Advanced breast cancer: observed responses with important limits

A 1975 report treated 43 people with disseminated or inoperable breast cancer. Eight of the 41 evaluable patients experienced objective remissions lasting longer than three months. Soft-tissue disease responded best, while liver and brain metastases did not respond in that series. Notter, 1975

Those findings demonstrate that responses were observed in a defined setting. They do not establish a survival advantage or prove that treatment is preferable to current alternatives. The abstract compares its efficacy and virilization with testosterone propionate, but does not describe a concurrent randomized comparison. That comparison should therefore not be presented as a definitive head-to-head result.

A 1981 retrospective review examined records of 66 women treated for metastatic breast cancer. Twenty-six experienced remission, with a reported mean duration of 8.2 months. Four patients had treatment interrupted for complications that included cholestasis, pulmonary embolism and high calcium levels. Hartmann and colleagues, 1981

A chart review cannot separate every contribution from cancer, other treatment and the androgen itself. In particular, those complications are not an event-rate estimate for healthy people. Equally, describing most patients as tolerating treatment does not erase the serious events. An accurate account keeps both the observed benefit and the uncertainty visible.

Refractory anaemia: improvement did not necessarily mean longer survival

In 1979, a report described 19 consecutive patients with several different types of refractory anaemia. Some patients in each diagnostic group had remission, but the authors did not observe an obvious survival extension among responders. The small, mixed population makes it difficult to know which diagnosis or patient characteristics predicted benefit. Lockner, 1979

This is a useful distinction for readers: improving a disease marker is meaningful, but it is not automatically the same as living longer or avoiding complications. Nor should a report involving several marrow disorders be collapsed into a broad statement that the drug treats every form of anaemia.

A 1988 randomized trial compared antithymocyte globulin alone with the same treatment plus oral methenolone in 30 patients with aplastic anaemia. Responses occurred in 11 of 15 receiving the combination and four of 15 receiving antithymocyte globulin alone. The response difference was statistically significant, while the reported survival difference was not. The authors described considerable toxicity and called for larger controlled studies. Kaltwasser and colleagues, 1988

The accessible abstract prints an inconsistent percentage beside the four-of-15 result; this review uses the counts rather than repeating that percentage. More importantly, this was an oral treatment study and does not establish the same effect for Primobolan Depot. It also does not demonstrate that methenolone alone would produce the combination's outcomes.

Liver injury: why a “mild” reputation is insufficient

A 1993 case report described a 75-year-old man with severe aplastic anaemia who had received several treatments before methenolone acetate. Liver enzymes rose markedly after methenolone began, followed by liver failure and death. Autopsy findings supported drug-induced injury, and the authors considered methenolone the most likely cause. Tsukamoto and colleagues, 1993

One case cannot determine how frequently an event occurs. The patient was seriously ill and had other exposures, and the formulation was acetate rather than depot enanthate. Those limits prevent a simple risk estimate, but the report also prevents a confident claim that the substance cannot cause serious liver harm. Formulation differences warrant precision, not dismissal of the event.

Other risks, interactions and populations needing caution

The Spanish label warns about liver tumors, virilization and premature bone maturation, and identifies pregnancy, severe liver or kidney impairment, liver tumors and certain cancers as contraindications. It flags additional caution with cardiovascular disease, hypertension, oedema and diabetes. Anticoagulant effects may increase, and glucose-lowering treatment may need medical reassessment. Breastfeeding exposure has not been established. AEMPS product information

The cardiovascular, reproductive and psychiatric risks of this particular molecule still need a fuller contemporary evidence review. The studies assembled here do not support a numerical comparison declaring it safer than other anabolic steroids. Likewise, a selected clinical series cannot establish safety in pregnancy, adolescents or people with multiple health conditions.

Canadian regulatory context

Anabolic steroids fall within Schedule IV of Canada's Controlled Drugs and Substances Act. A foreign medicines label and a historic research paper do not resolve Canadian product authorization. This review did not establish a current Canadian Drug Product Database entry for metenolone or Primobolan Depot; that remains an unresolved research item, not proof that no entry exists. Official Canadian schedule

Product availability, medical appropriateness and controlled-substance rules are separate questions. No sourcing or importation advice is provided here.

Questions this evidence cannot answer